Evaluating Twitter as a complementary data source for pharmacovigilance

Expert Opin Drug Saf. 2018 Aug;17(8):763-774. doi: 10.1080/14740338.2018.1499724. Epub 2018 Jul 26.

Abstract

Background: Social media are currently considered as a potential complementary source of knowledge for drug safety surveillance. Our primary objective was to estimate the frequency of adverse drug reactions (ADRs) experienced by Twitter users. Our secondary objective was to determine whether tweets constitute a valuable and informative source of data for pharmacovigilance purposes, despite limitations on character number per tweet.

Research design and methods: We selected a list of 33 drugs subject to careful monitoring due to safety concern in France and Europe, and extracted tweets using the streaming API from 30 September 2014 to 5 April 2015. Two pharmacovigilance centers classified these tweets manually as potential ADR case reports.

Results: Among 10,534 tweets, 848 (8.05%) implied or mentioned an ADR without meeting the four FDA criteria required for reporting an ADR, and 289 (2.74%) tweets were classified as 'case reports.' Among them 20 (7.27%) tweets mentioned an unexpected ADR and 33 (11.42%) tweets mentioned a serious ADR.

Conclusions: With the use of dedicated tools, Twitter could become a complementary source of information for pharmacovigilance, despite a major limitation regarding causality assessment of ADRs in individual tweets, which may improve with the new limitation to 280 characters per tweet.

Keywords: Pharmacovigilance; Twitter; causality assessment; social media.

MeSH terms

  • Data Collection / methods
  • Drug-Related Side Effects and Adverse Reactions / epidemiology*
  • Europe
  • France
  • Humans
  • Pharmacovigilance*
  • Social Media / statistics & numerical data*